Elkem Labs as a share of promoter family entity Rs. 930 crore sees block deals; Major buyers include Goldman, Morgan Stanley

On Tuesday, shares of Alchem ​​Laboratories traded at around Rs. 930 crore block deals were seen, in which promoter family entities sold shares to domestic mutual funds and foreign institutional investors. According to NSE block deal data, a total of 17.88 lakh shares worth Rs. 5,200 were exchanged. The transaction value is around Rs 930 crore.

On the selling side, Jayanthi Sinha sold 12.38 lakh shares, while Samprada and Nanhmati Singh Family Trust sold 5.5 lakh shares. The two sellers together sold 17.88 lakh shares. These shares were acquired by a mix of local and foreign institutional investors.

Among the biggest buyers were ICICI Prudential Mutual Fund, which bought 9.04 lakh shares, and HDFC Mutual Fund, which bought 5.1 lakh shares. Other participants include DSP Mutual Fund, Nippon India Mutual Fund, Morgan Stanley Asia Singapore, Goldman Sachs Bank Europe, BNP Paribas Arbitrage, Societe Generale and Edelweiss Mutual Fund.

The deal comes after a strong run in Elchem ​​Laboratories shares over the past year, supported by continued growth in its domestic formulations business, improving margins and recovery in its US operations.

Alkem is one of India’s leading pharmaceutical companies with a strong presence in acute care, chronic segments and international markets. The participation of large domestic mutual funds in the transaction indicates continued institutional interest in quality healthcare names despite broader market volatility.

Alchem ​​Laboratories shares are likely to remain in focus as investors assess the impact of the stake sale and changes in the promoter’s shareholding following the transaction.